0000899243-21-035564.txt : 20210910
0000899243-21-035564.hdr.sgml : 20210910
20210910170022
ACCESSION NUMBER: 0000899243-21-035564
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210908
FILED AS OF DATE: 20210910
DATE AS OF CHANGE: 20210910
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Dainippon Sumitomo Pharma Co Ltd
CENTRAL INDEX KEY: 0001446601
STATE OF INCORPORATION: M0
FISCAL YEAR END: 0331
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37929
FILM NUMBER: 211247680
BUSINESS ADDRESS:
STREET 1: 60 WALL STREET
CITY: NEW YORK
STATE: NY
ZIP: 10005
BUSINESS PHONE: 212-319-7600
MAIL ADDRESS:
STREET 1: 60 WALL STREET
CITY: NEW YORK
STATE: NY
ZIP: 10005
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Sumitomo Chemical Co., Ltd.
CENTRAL INDEX KEY: 0001798550
STATE OF INCORPORATION: M0
FISCAL YEAR END: 0331
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37929
FILM NUMBER: 211247681
BUSINESS ADDRESS:
STREET 1: 27-1, SHINKAWA 2-CHOME
STREET 2: CHUO-KU
CITY: TOKYO
STATE: M0
ZIP: 104-8260
BUSINESS PHONE: 813-5543-5142
MAIL ADDRESS:
STREET 1: 27-1, SHINKAWA 2-CHOME
STREET 2: CHUO-KU
CITY: TOKYO
STATE: M0
ZIP: 104-8260
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Sumitovant Biopharma Ltd.
CENTRAL INDEX KEY: 0001798244
STATE OF INCORPORATION: D0
FISCAL YEAR END: 0331
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37929
FILM NUMBER: 211247679
BUSINESS ADDRESS:
STREET 1: SUITE 1, 3RD FLOOR
STREET 2: 11-12 ST. JAMES SQUARE
CITY: LONDON
STATE: X0
ZIP: SW1Y 4LB
BUSINESS PHONE: (646) 802-3660
MAIL ADDRESS:
STREET 1: C/O ROIVANT SCIENCES, INC.
STREET 2: 320 WEST 37TH STREET, 5TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10018
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Myovant Sciences Ltd.
CENTRAL INDEX KEY: 0001679082
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: CA
FISCAL YEAR END: 0331
BUSINESS ADDRESS:
STREET 1: SUITE 1, 3RD FLOOR
STREET 2: 11-12 ST. JAMES SQUARE
CITY: LONDON
STATE: X0
ZIP: SW1Y 4LB
BUSINESS PHONE: 44 207-400-3351
MAIL ADDRESS:
STREET 1: SUITE 1, 3RD FLOOR
STREET 2: 11-12 ST. JAMES SQUARE
CITY: LONDON
STATE: X0
ZIP: SW1Y 4LB
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-09-08
0
0001679082
Myovant Sciences Ltd.
MYOV
0001798550
Sumitomo Chemical Co., Ltd.
27-1, SHINKAWA 2-CHOME
CHUO-KU, TOKYO
M0
104-8260
JAPAN
0
0
1
0
0001446601
Dainippon Sumitomo Pharma Co Ltd
6-8 DOSHOMACHI 2-CHOME
CHUO-KU, OSAKA
M0
541-0045
JAPAN
0
0
1
0
0001798244
Sumitovant Biopharma Ltd.
11-12 ST. JAMES'S SQUARE SUITE 1
3RD FLOOR
LONDON
X0
SW1Y 4LB
UNITED KINGDOM
0
0
1
0
Common Stock
2021-09-08
4
P
0
21902
25.7357
A
49317180
I
See Footnote
Common Stock
2021-09-09
4
P
0
37000
25.5175
A
49354180
I
See Footnote
This acquisition of a total of 21,902 ordinary shares on the open market is pursuant to a Rule 10b5-1 Stock Trading Plan entered into by the Reporting Person on May 14, 2021 (the "10b5-1 Trading Plan").
The transaction was executed in multiple trades ranging from $25.26 to $26.23 per share. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide, upon request by the Commission Staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transactions were effected.
Sumitovant Biopharma Ltd. ("Sumitovant") directly owns a total of 49,317,180 shares of Common Stock following the acquisition on September 8, 2021. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. ("Sumitomo Dainippon"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. ("Sumitomo Chemical"). Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein.
This acquisition of a total of 37,000 ordinary shares on the open market is pursuant to the 10b5-1 Trading Plan.
The transaction was executed in multiple trades ranging from $25.14 to $26.00 per share. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide, upon request by the Commission Staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transactions were effected.
Sumitovant directly owns 49,354,180 shares of Common Stock following the acquisition on September 9, 2021. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon, which is a 51.76% owned subsidiary of Sumitomo Chemical. Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein.
Sumitomo Chemical Co., Ltd., By: /s/ Swathi Padmanabhan, as Attorney-in-Fact
2021-09-10
Sumitomo Dainippon Pharma Co., Ltd., By: Tsutomu Nakagawa, Senior Director, Global Corporate Strategy, /s/ Tsutomu Nakagawa
2021-09-10
Sumitovant Biopharma Ltd., By: /s/ Swathi Padmanabhan, as Attorney-in-Fact
2021-09-10